HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas.

AbstractPURPOSE:
To evaluate the efficacy of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas.
METHODS:
A retrospective, consecutive, nonrandomized, comparative single-masked cohort study of all patients presenting with nonvision-threatening periocular infantile capillary hemangiomas between August 2007 and January 2011 was performed. Parents chose twice daily topical 0.25% timolol maleate gel or observation. Photographs were taken at all visits and subsequently evaluated by masked examiners for change in lesion size, color, and thickness. Lesions were clinically defined as superficial, mixed, or deep. The primary outcome was response to treatment at 2 months, categorized as good (size decreased .50%), moderate (decrease 0-50%), or poor (enlarged or caused visually significant ptosis or induced astigmatism). The secondary outcome was response at latest follow-up visit.
RESULTS:
Thirteen children received timolol, and 10 children were observed, with mean ages at presentation of 4.8 and 3.7 months (p 5 0.31), respectively. In the treated group, good response was observed in 8 (61.5%) infants, moderate response was seen in 4 (30.8%), and poor response was seen in one patient (7.7%). In the observed group, 0 (0%) demonstrated good response, one (10%) demonstrated moderate response, and 9 demonstrated poor response (90%) (p , 0.001). Responses were consistent on long-term follow-up (range 3-41 months). Both superficial (n 5 5; 100% good response) and mixed (n 5 7; 43% good, 57% moderate) lesions responded well to timolol; the one deep lesion did not. No adverse ocular or systemic effects were observed.
CONCLUSIONS:
Topical timolol maleate gel 0.25% is effective in treatment of nonvision-threatening infantile capillary hemangiomas with a superficial component. Response at 2 months is stable over time.
AuthorsChristopher B Chambers, William R Katowitz, James A Katowitz, Gil Binenbaum
JournalOphthalmic plastic and reconstructive surgery (Ophthalmic Plast Reconstr Surg) 2012 Mar-Apr Vol. 28 Issue 2 Pg. 103-6 ISSN: 1537-2677 [Electronic] United States
PMID22410658 (Publication Type: Comparative Study, Controlled Clinical Trial, Journal Article)
Chemical References
  • Adrenergic beta-Antagonists
  • Gels
  • Timolol
Topics
  • Administration, Topical
  • Adrenergic beta-Antagonists (administration & dosage)
  • Follow-Up Studies
  • Gels
  • Hemangioma, Capillary (drug therapy, pathology)
  • Humans
  • Infant
  • Orbital Neoplasms (drug therapy, pathology)
  • Retrospective Studies
  • Single-Blind Method
  • Skin Neoplasms (drug therapy, pathology)
  • Timolol (administration & dosage)
  • Treatment Outcome
  • Visual Acuity (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: